We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...

Metsera is engaged in the development of injectable ... address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health ...

Metsera is engaged in the development of injectable ... address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health ...

MET-097i achieved up to 11.3% mean placebo-adjusted weight loss at 12 weeks and exhibited a 380-hour (nearly 16-day) half-life and good tolerability. Metsera said the drug's profile is at least as ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.